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Abstract
Thyroid cancer is the ﬁfth most common cancer diagnosed in women worldwide. Notwithstanding advancements in
the prognosis and treatment of thyroid cancer, 10–20% of thyroid cancer patients develops chemotherapeutic
resistance and experience relapse. According to previous reports and TCGA database, MUC15 (MUCIN 15) upregulation
is highly correlated with thyroid cancer progression. However, the role of MUC15 in tumor progression and metastasis
is unclear. This study aimed to investigate factors mediating cancer stemness in thyroid cancer. MUC15 plays an
important role in sphere formation, as an evident from the expression of stemness markers including SOX2, KLF4,
ALDH1A3, and IL6. Furthermore, ectopic expression of MUC15 activated extracellular signal-regulated kinase (ERK)
signaling via G-protein–coupled receptor (GPCR)/cyclic AMP (cAMP) and integrin/focal adhesion kinase pathways.
Interestingly, ectopic expression of MUC15 did not affect RAF/mitogen-activated protein kinase kinase (MEK)-mediated
ERK activation. The present ﬁndings may provide novel insights into the development of diagnostic, prognostic, and
therapeutic applications of MUC15 in thyroid cancer.
Introduction
According to reports of National Cancer Institutes
(NCI), thyroid cancer has shown a signiﬁcant increase
over the last 30 years1. Although thyroid cancer has a
good prognosis and is considered easily curable via sur-
gical resection and radio-iodine based therapies, 10–20%
of thyroid cancer cases involve aggressive behavior
including local invasion, distant metastasis, drug
resistance, recurrence, and mortality2–5. Since thyroid
carcinoma is at a high risk of invasion, recurrence, and
metastasis, it is important to study the underlying mole-
cular mechanism.
A crucial cancer stem cell (CSC) population causes
these malignant phenotypes in various cancers6–10, espe-
cially thyroid cancer11,12. Indeed CSCs can be veriﬁed
through clonogenic assays of cells to assess proliferative
capacity including sphere formation in vitro13,14 or via
in vivo tumorigenesis experiments15. Current radio-
therapy and chemotherapy often eliminate the bulk of
cancer cells but not CSCs, which are protected via speciﬁc
resistance mechanisms16,17. These unsolved issues may be
explained on the basis of CSC-like properties of many
tumor types6,11,18,19. We found that one isoform of
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mucins, MUC15 play a critical role of mediating cancer
stemness in thyroid cancers.
Mucins are high-molecular-weight membrane glyco-
proteins (>200 kDa) in various types of epithelial
cells20–22. Secreted form of mucins have a protective
functional epithelial barrier to protect against from bac-
teria and virus infections21 while membrane-associated-
mucin proteins are intracellular receptors involved in
signal transduction, leading to coordinated cellular
responses including proliferation, differentiation, apop-
tosis, and secretion of specialized cellular products23,24.
MUC15 upregulation is signiﬁcantly correlated with
various types of cancers such as colon cancer, hepato-
cellular carcinoma, and especially thyroid cancer25–27.
High cancer scores of MUC15 expression are signiﬁcantly
correlated with age, distant metastasis, and the presence
of multifocality26. In addition, ectopic MUC1 expression
upregulates CSC markers in breast cancer and lung can-
cer such as OCT4, SOX2, ALDH1A1, IL6, and
CXCR417,28,29. Moreover, MUC1 upregulation has been
considered to signiﬁcantly contribute to the aggressive-
ness of the papillary thyroid cancer (PTC)30. Similarly,
MUC4 is known to be upregulated in 20% of PTC cells
compared to normal cells26,31 and is correlated with the
development of chemoresistance in pancreatic CSC32.
These results imply that mucins play an important role in
mediating tumor development and progression and are
related to cancer stemness properties in thyroid cancer
and various types of cancer17,29,33,34. However, its phy-
siological role and its underlying molecular mechanisms
in thyroid cancer progression and metastasis are unclear.
The RAS-ERK pathway mediates cancer progression,
metastasis, and cancer stemness in various types of can-
cer35–37. Furthermore, G-protein-coupled receptor
(GPCR) and integrin-focal adhesion kinase (FAK) signal-
ing are upstream targets of activated extracellular signal-
regulated kinase (ERK)38,39, thereby increasing the stem-
ness of thyroid cancer cells.
This study aimed to investigate the correlation between
CSC-like properties and thyroid cancer progression and
metastasis because CSCs are crucial for cancer recur-
rence, metastasis, and drug resistance, which are yet
unclear. Our results may provide novel insights into help
understand physiological and cellular mechanisms of
recurrence and metastasis in thyroid cancer and the
characteristics of thyroid CSC, and in developing novel
therapeutic targets for thyroid cancer patients.
Results
MUC15 is upregulated in later stages of thyroid cancer
Thyroid tumors display greaterMUC15 expression than
neighboring normal thyroid epithelial cells26. These
ﬁndings are concurrent with those of our clinical studies.
Mostly thyroid tumors in patients have greater MUC15
expression than normal tissue, especially in higher-grade
tumors (Fig. 1a, b). To clarify the role of MUC15 in
thyroid cancer progression, we ﬁrst examined MUC15
expression in thyroid cancer cells (FTC-238 and TPC-1),
relative to that of normal thyroid cells (Nthy-ori-3-1).
Metastatic thyroid cancer cells (FTC-238) displayed
upregulated MUC15 expression compared to normal
thyroid epithelial cells; in particular, FTC-238 cells dis-
played signiﬁcantly upregulated MUC15 expression
(greater than 20 folds) than Nthy-ori-3.1 cells (p=
0.0014); however, TPC-1 (non-metastatic cancer cells) did
not display a signiﬁcant difference (Fig. 1c and Supple-
mentary Figure S1D). Consistent with reverse transcrip-
tion PCR (RT-PCR) results, western blot as well as and
immuno-ﬂuorescence analyses conﬁrmed increased
MUC15 expression in thyroid cancer cells (Fig. 1e). These
ﬁndings are conﬁrmed via TCGA database using GEPIA
website based on a published dataset at 2014 (http://gepia.
cancer-pku.cn/) (Fig. 1d and Supplementary Figure
S1A)40,41. In addition, thyroid cancer patient with high
level of MUC15 show worse prognosis analyzed by
cBioPortal (http://www.cbioportal.org/) and GEPIA
(http://gepia.cancer-pku.cn/) websites respectively (Sup-
plementary Figure S1B, C)41,42.
Ectopic MUC15 expression promotes CSC-like properties
Metastasis and chemotherapeutic resistance are associated
with properties of CSCs in various types of cancers18,43–45.
Sphere formation is a key characteristic of stem cells and
CSCs; hence, this characteristic is harnessed in analyzing
properties of cancer stemness34,46–48. While investigating
the physiological role ofMUC15 in thyroid cancer, we found
that FTC-238 cancer cells display greater sphere formation
abilities; however, Nthy-ori-3-1 and TPC-1 cells did not
adequately generate spheres (Fig. 2a, b).
To conﬁrm the function ofMUC15 in sphere formation,
we knocked down MUC15 in FTC-238 with lentiviral
MUC15 shRNA (Supplementary Figure S2A and C).
Consequently, sphere formation abilities of MUC15
shRNA-transduced cells were lower than those of control
cells (cells transfected with the vector control) (Fig. 2c, d).
These data together suggest MUC15 expression is
strongly associated with sphere formation among thyroid
cancer cells.
To further verify whether MUC15 regulates sphere
formation, we transducedMUC15 expressing lentivirus to
Nthy-ori-3-1 cells to generate cells stably overexpressing
MUC15, referred to as MUC15 overexpress cells
(MUC15-OV cell) (Supplementary Figure S2B, D, E and
F). Interestingly, these cells displayed enhanced sphere
formation ability, implying CSC-like properties (Fig. 2e, f).
We also quantiﬁed the number and size of spheres
between Nthy-ori-3-1 and MUC15-OV cells. Although
both Nthy-ori-3-1 and MUC15-OV cells could form
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spheres of 50–100 and 100–150 µm, MUC15-OV cells
exhibited numerous colonies. In particular, spheres of
greater than 250 µm were only found in MUC15-OV cells
(Fig. 2g).
The expression level of stem cell markers SOX2, OCT4,
and KLF4 in MUC15-OV cells were 2.38, 1.45, and 40.1
folds higher than those in normal thyroid epithelial cells,
NThy-ori-3.1, respectively (Fig. 2h). Additionally, the
expression level of ALDH1A3, a CSC marker among
various types of cancer cells49, and IL6 known as a
downstream functional target to induce sphere formation
in many types of cancer cells50–53, were 22.9 and 3.09
folds higher inMUC15-OV cells than in Nthy-ori-3.1 cells
(Fig. 2h).
Fig. 1 MUC15 is highly expressed in Thyroid cancer tissue and cell line. a Relative expression level of MUC15 between tumor (25 cases) and their
neighboring normal thyroid tissue (27 cases) in thyroid cancer patients. b MUC15 Immunohistochemical (IHC) positivity in the patients was scored
from 0 to 3 according to the percentage positivity (grade 0, 0%; grade 1, 1–33%; grade 2, 34–66%; grade 3, 67–100%). c Relative expression level of
MUC15 normalized by GAPDH expression level among Nthy-ori-3-1, TPC-1, and FTC-238 cells. Western blots showing the expression level of the
MUC15 protein. d Thyroid tumors have enhanced expression of MUC15 in patients according to TCGA database. e Immunostaining of MUC15 in
Nthy-ori-3-1, TPC1 and FTC-238 cells, respectively
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In addition, ectopic MUC15 expression increases cel-
lular survival and proliferation even in adhered cells. The
data show that the number of MUC15-OV cells was
higher than that of Nthy-ori-3.1 cells during suspension
culture (Supplementary Figure S3A). Moreover, MUC15-
OV cells showed a low population of apoptotic cells in
suspension culture, especially 3 and 5d after incubation, as
determined via FACS (Supplementary Figure S3B, C).
Since MUC15 could inhibit apoptosis, thereby increasing
the number of survived cells in suspension culture, this
property is correlated with metastasis and CSC-like
properties25.
Fig. 2 Over-expression of MUC15 drives cancer stem cell properties. a, b Representative images showing sphere formation among Nthy-ori-3-1
cells, TPC-1 and FTC-238 cells and quantitative values measured size of sphere from the results. c, d Representative images show sphere formation
ability among transfected with Empty vector and indicated MUC15 shRNA respectively and quantitative values measured size of sphere from the
results. e–g Representative images showing sphere formation between Nthy-ori-3-1 and MUC15-OV (MUC15 overexpression) cells and quantitative
values measured size of sphere from the results. h RT-qPCR data show that MUC15 over expression cell increased the expression of stem cell markers
SOX2, OCT4, KLF4 and cancer stem cell markers ALDH1A3 and IL6
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MUC15 activates the MEK-ERK pathway independent of
BRAF
MUC15 induces the activation of oncogenic ERK acti-
vation, thereby mediating metastasis in colon cancer25.
MUC1 could activate ERK-C/EBP beta signaling in breast
cancer cells28. MUC4 triggers ERK activation dependent
on conﬂuence of mammary epithelial and tumor cells54.
These ﬁndings together suggest that MUC15 may also
activate ERK signaling in thyroid epithelial cells. Thus, we
investigated whether over-expression of MUC15 increases
ERK phosphorylation. Indeed, MUC15-OV cells showed
increased MEK and ERK phosphorylation (Fig. 3a). How-
ever, we could not observe differences in BRAF activation
on adding hEGF (100 ng/ml) between Nthy-ori-3.1 and
MUC15-OV cells, although the initial state of MEK and
ERK phosphorylation was enhanced in MUC15-OV cells
(Fig. 3b). Previously, activation of ERK is associated with
CSC-like properties and sphere formation34. ERK sup-
pression with pharmacological inhibitor UO126 decreased
sphere formation in MUC15-OV cells (Fig. 3c, d). These
observations suggest that MUC15 plays an important role
in developing CSCs via the MEK-ERK pathway.
MUC15 induces expression of genes related to the GPCR-
cAMP pathway, thereby increasing ERK phosphorylation
Sphere formation is regulated by various signaling
pathways that promote CSCs. To determine signaling
pathway involves MUC15, we performed next-generation
sequencing (NGS) for total mRNA and compared the
expression of numerous genes between Nthy-ori-3-1 and
MUC15-OV cells, using a log2 scale heat-map via MeV
program (Fig. 4a)55. Differentially expressed target genes
were analyzed in silico to further analyze enriched sig-
naling pathways through the Carcinogenic Potency
Database (CPDB) molgen website (http://cpdb.molgen.
mpg.de/) and GO-term analysis using PANTHER (http://
pantherdb.org/)56,57. These two different tools revealed
that the molecular signaling pathway related to MUC15 is
the GPCR pathway (Supplementary Figure S4A, B, Table
S1 and Table S2). We conﬁrmed the expression of GPCR-
Fig. 3 MUC15 drives activation of MEK/ERK independent to BRAF. a The level of phosphorylation ERK1/2 and total ERK1/2 in MUC15 over
expression cell are higher than Nthy-ori cell. b Nthy-ori and MUC15 over expression cells were treated with either serum or hEGF for 10, 30, 60 min
and RAF/MEK/ERK protein expression were determined by immunoblotting. c, d Blocking ERK activity by UO126 (10 µM) were determined by
immunoblotting and inhibition of ERK decreased mammosphere formation ability of MUC15 over expression cells
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Fig. 4 GPCR signaling pathway is candidate downstream target of MUC15. MUC15 drives activation of ERK via GPCR-cAMP signaling pathway
independent to RAF/MEK, associated to FAK signaling. a GPCR signaling was determined as a downstream target of MUC15 by using RNA-SEQ
analysis. b–d RT-PCR and RT-qPCR and western blot data represented the gene upregulated of GPCR signaling pathway in MUC15 overexpression cell
and Nthy-ori cell. e, f Nthy-ori and MUC15 overexpression cell were treated with PTX, an inhibitor of GPCR and Caffeine, an inhibitor of cAMP. The
protein expression was determined by immunoblotting. g Nthy-ori and MUC15 over expression cells were treated PF-573228 as 10 μM, as an inhibitor
of FAK, and protein levels of MEK/ERK were determined by immunoblotting
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related genes in response to MUC15 via RT-qPCR and
western blot analysis (Fig. 4b–d). As shown in Fig. 4b;
CCR7, C3 expression level inMUC15-OV cell was greater
than eight-folds and two-folds than those in Nthy-ori-
3.1 cells, respectively.
Together, RNA-SEQ analysis and western blot analysis
displaying that over-expression of MUC15 mediates
activation of ERK, we hypothesized that MUC15 may
induce activation of ERK via a GPCR pathway rather than
RAS-RAF pathway, in accordance with a previous study58.
Previously, cells were treated with pertusis toxin (PTX)
(200 ng/ml) to inhibit the GPCR signaling pathway59. PTX
is known to catalyze the ADP-ribosylation of the αi sub-
units of the heterotrimeric G protein60. Interestingly,
phosphorylation level of ERK of MUC15-OV cells was
decreased with PTX treatment after 4 h (Fig. 4e). This
inhibitor can block the activation of ERK, although
phosphorylation levels of BRAF and MEK were not
altered mediated by MUC15 over-expression (Fig. 4e).
These results demonstrate that MUC15 activate GPCR-
ERK signaling; however, the involvement of other path-
ways cannot be eliminated. We were curious about which
downstream signaling pathway mediates GPCR-ERK sig-
naling independent on MEK activation. cAMP is known
as the second messenger to activate ERK in endocrine
cells mediated by GPCR signaling pathway independent of
MEK activation61. Therefore, we wanted to investigate
whether inhibition of cAMP production by caffeine
treatment (1 mM) decreases the activation of ERK without
affecting MEK phsophorylation62. Surprisingly, treatment
with caffeine drastically decreased the activation of ERK,
but not MEK in both Nthy-ori-3-1 and MUC15-OV cell
lines (Fig. 4f).
These ﬁndings raise the question why MUC15 may
drive ERK activation via GPCR/CAMP pathway but sti-
mulate MEK/ERK activation through another pathway.
GPCR crosstalk with FAK signaling is critical to activate
ERK activation63. MUC5AC mediates metastasis of cancer
cells by interacting with integrin β4–FAK signaling in
lung cancer cells64. We hence set to investigate whether
FAK signaling may be associated with ERK activation
triggered by MUC15 over-expression. Interestingly, FAK
inhibitor (PF-00562271) can suppress activation of MEK
and ERK in MUC15-OV cells (Fig. 4g). Previous ﬁndings
and these results together indicate that over-expression of
MUC15 could activate MEK-ERK signaling by the integ-
rin-FAK signaling pathway.
The GPCR-cAMP pathway is critical to sustain sphere
formation and motile behavior of thyroid cancer mediated
by MUC15 over-expression
MUC15 enhanced sphere formation and the GPCR-
cAMP axis is important for the activation of ERK sig-
naling mediated by MUC15 (Fig. 4). Therefore, we
investigated whether the GPCR-cAMP axis is involved in
sphere formation in thyroid cancer. Interestingly, PTX or
caffeine treatment reduces sphere formation ability
of MUC15-OV cells and FTC-238 cells respectively
(Fig. 5a, b). In addition, these drugs also decrease known
stemness markers such as SOX2, OCT4, KLF4 CD44, and
ALDH1A3 (Fig. 5c). Together, we concluded that exo-
genously expressed MUC15 induces the expression of
genes related to the GPCR signaling pathway and triggers
activation of the GPCR-cAMP-ERK pathway independent
of the RAF/MEK signaling pathway.
However, the functional role of MUC15 on cell migra-
tion is controversial. In hepatocellular carcinoma and
trophoblast-like cells, MUC15 decrease migration cap-
ability27,65. Whereas, in case of colon cancer, MUC15
drives invasive migration through boyden chambers,
thereby enhancing metastasis25. In our study, there was
no major difference between Nthy-ori-3-1 and MUC15-
OV cells for wound healing migration capability (Fig. 5d).
However, inhibition of GPCR or cAMP signaling by PTX
and caffeine, respectively, decreased wound healing
migration in MUC15-OV cells (Fig. 5d, e). However,
caffeine treatment selectively suppresses migration
ability of MUC15-OV cells, but not Nthy-ori-3-1 cells
(Fig. 5d, e). These observations imply that MUC15
somehow has an inhibitory role of migration such as
strong adhesion; however, activation of GPCR-cAMP
signaling pathway compensates the ability of migration.
MUC15 enhanced tumorigenesis in NOD/SCID mice
To conﬁrm cancer stem-like capacity driven by MUC15
in vivo, we additionally performed a tumorigenesis
experiment using a xenograft mouse model. First, we
generated lentiviral-mediated control or MUC15 shRNA
knockdown cells in FTC-238, wherein MUC15 was
overexpressed, compared to Nthy-ori-3-1 and TPC-1
cells. These lentiviral vectors containing tGFP thereby
transfected cells, which could then be detected by the
IVIS imaging system. These cells were injected sub-
cutaneously into the belly in NOD/SCID mice and the
mice were monitored for up to 30 days. Interestingly, the
signal of tGFP from FTC-238 control cell has signiﬁcantly
higher intensity than that of MUC15 knockdown cells in
all of monitoring (Fig. 6a–c and Supplementary Figure
S5B). In addition, FTC-238 cells bearing control shRNA
generated larger-sized tumors than those transfected with
MUC15 shRNA (Supplementary Figure S5A). These data
indicate that MUC15 is closely associated with tumor-
igenesis and carcinogenesis.
Discussion
Regardless of cell type to be initiated, various types of
tumors develop in the thyroid gland, such as papillary (the
most common), follicular, medullary, and anaplastic (the
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least common) tumors. Although most types of thyroid
tumors are benign, there are still some types of tumors
that can be malignant and metastatic, recurrent, and even
display chemotherapeutic resistance. Several studies
conﬁrmed various vital signaling pathways that modulate
embryonic development and stem cell maintenance.
However, aberrant regulation of these intrinsic biological
processes may have harmful effects on neoplastic trans-
formation. Nowadays, it is reported that normal stem cells
can transform to CSC, thereby promoting malignancy66.
Cancer stemness is considered a critical feature to
mediate malignancy of cancer such as metastasis, recur-
rence, drug resistance in many types of cancer as well as
thyroid cancer11,16. It led us to investigate what factors
Fig. 5 GPCR-cAMP pathway regulates motility and migration of thyroid cancer cells. a, b Sphere formation ability of cell lines express MUC15,
MUC15 overexpression cell and FTC-238, are reduced after treated with PTX (200 ng/ml) and Caffeine (1 mM). c The expression level of stem cell and
cancer stem cell in MUC15 overexpression cell were determined by RT-qPCR. d, e The migration of Nthy-ori cell and MUC15 overexpression cell after
treated with PTX (200 ng/ml) and caffeine (1 mM)
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mediate cancer stemness in thyroid cancer. We identiﬁed
MUC15 plays a key role in the progression of tumor-
genesis by enhancing cancer stemness in thyroid cancer.
Either gain or loss of function study demonstrates that
MUC15 is necessary and sufﬁcient factor to induce fea-
ture of thyroid CSC. The MUC15 expression is higher in
follicular thyroid cancer cells, especially FTC-238 cell line,
while TPC-1 cells derived from primary thyroid cancer
does not show enhanced expression of MUC15. In con-
sistent with previous studies, our results show that
MUC15 play a positive role of developing thyroid cancer
progression67.
Our data indicate that MUC15 expression enhanced
sphere formation, the renewal characteristic of stem-like
properties. In addition, MUC15 expression increases
several vital genes to mediate CSC properties, SOX2,
KLF4 and IL-6 in normal thyroid epithelial cells (Fig.
2h)51,53. Consistent with the previous reports, MUC15
indeed drives the invasive behavior of colon cancer and
metastasis25. Collectively, our results suggest thatMUC15
play an important role in developing CSC thereby mediate
metastasis and recurrence of thyroid cancer.
CSC are developed by hijacking intrinsic signaling
pathway which mediates progression of normal embryo-
nic development in stem cells. This pathway is also known
as key player to modulate normal embryonic development
as well68,69. The GPCR pathway is thought to be related to
the stem cell function by the fact that the pattern of
expression of GPCR varies greatly at each step during
embryonic development or differentiation70. This ability
allows tumor to be regenerated after anti-cancer therapy
by chemotherapy or radiotherapy.
GPCR signaling pathway closely associated with cancer
stemness in thyroid cancer according to previous studies71.
Consistent with this, we found MUC15 induces expression
of several class of GPCR signaling related genes and confer
properties of cancer stemness by the GPCR pathway. These
genes that mediate GPCR signaling pathway are highly up-
regulated in MUC15-OV cells such as CCR7, C3, CCL20,
and C5AR1 (Fig. 4b–d). CCR7, one of chemokine receptor
involved in GPCR families, it is identiﬁed as tumor pro-
gression marker in thyroid cancer patients72. In the pre-
vious report, CCR7 mediates activation of ERK thereby
suppresses apoptosis in lung cancer73. CCR7 also promotes
Fig. 6 MUC15 expression enhanced tumorigenesis in NOD/SCID mice. a, b The GFP signal imaging after 30 days inject FTC-238 control, FTC-238
MUC15 knockdown (FTC-238-SH) respectively. c The radiant efﬁciency of GFP signals from 1 day to 30 day after injection thyroid cancer cells
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mammary tumorigenesis through amplication of stem-like
cell74. CCL20 is identiﬁed as inﬂammatory factor to recruit
dendritic cells75. Production of CCL20 by lung cancer could
induce cell migration and proliferation via PI3K signaling
pathway as well76. Recent study suggests that inﬂammatory
CCL20 is also required to maintain CSC in breast cancer77.
In addition, we found some up-regulated genes, ADRA2C,
C3, and C5AR1, which were not previously reported in
cancer stemness. These ﬁndings may provide novel candi-
date markers to identify CSC in thyroid as well as other
types of cancer.
Important downstream target of GPCR signaling path-
way is cAMP-PKA pathway. Subunit of GPCR, the Gαs
and Gαi/o are able to trigger activation of adenylate
cyclase to modulate production of cyclic AMP (cAMP)
and cascadic activation of protein kinase A (PKA)78,79.
Treatment of caffeine as inhibitor of adenylate cyclase
suppresses the proliferation and migration of the cell
expressing high level of MUC15 (Fig. 5). This result
indicates that cAMP plays a critical role to promote
sphere formation and ERK activation mediated by
MUC15. It is reported that caffeine consuming such as
coffee uptake reduce the risk of several types cancers
including breast, colon80. These clinical studies may
associate with our ﬁnding that caffeine effectively
decreases CSC properties and migration ability (Fig. 5).
Ectopic expression of MUC15 increase activation of
ERK signaling pathway but BRAF does not seem to be a
downstream target ofMUC15, although BRAF reported in
many case of thyroid cancer81. Furthermore, there are
cross-talks between GPCR and integrin signaling in cell
proliferation the activation of some GPCR component can
activate FAK and stimulate the activation of MEK/ERK
signal82,83, it is consistent with the activation of FAK and
GPCR association with MUC15 expression (Fig. 4e–g).
Taken together, we suggest thatMUC15 mediated GPCR-
cAMP signaling pathway, which crosstalk with integrin-
FAK signaling are critical to driving sphere formation via
ERK activation independent to RAS-RAF signaling (Fig. 7).
MUC15-mediated signaling pathway contributes a key
characteristic of CSC and confers opportunities to
development novel therapeutic strategies and diagnostic/
prognostic markers for thyroid cancer patients. Further
investigation of MUC15-mediated gene expression and
downstream signaling pathway will elucidate self-renewal
properties of CSC for highly tumorigenic population of
CSC in thyroid cancer.
Materials and methods
Cell culture
The cell lines used to recapitulate human thyroid cancer
were FTC-238, derived from follicular thyroid carcinoma
(FTC) lung metastasis from a 42-year-old man, and TPC-1,
derived from a weak metastatic papillary thyroid carcinoma
(PTC)70. Human thyroid epithelial cell line Nthy-ori 3-1
constituted the control. Cancer cells were cultured with
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Mediatech
Cellgro, USA) containing 10% fetal bovine serum (FBS)
(Gibco, USA), 100 IU/ml penicillin, and 100 µg/ml strep-
tomycin (Invitrogen, USA). Epithelial cells were cultured
with Roswell Park Memorial Institute medium (RPMI)
(Mediatech Cellgro) containing 10% FBS 100 IU/ml peni-
cillin, and 100 µg/ml streptomycin. Cells were cultured at
37 °C and 5% CO2.
In vivo tumorigenicity assay
All animal work was conducted in accordance with a
protocol approved by the Institutional Animal Care and
Use Committee at Soonchunhyang University. MUC15
tumorigenicity in vivo was investigated using a xenograft
tumor model in the NOD/SCID mice. Eight-week-old
male NOD/SCID mice were provided sterilized food and
water and equally divided into three groups. Approxi-
mately 1 × 106 cells with or without MUC15 shRNA and
control shRNA (vector control) were mixed with Matrigel
(Corning, USA) and subcutaneously inoculated into the
right ﬂank of each NOD/SCID mice. These cells contain
Fig. 7 Schematic diagram of cell signaling pathway regulated by
MUC15. Over-expression of MUC15 activate MEK-ERK pathway
dependent on integrin-FAK and GPCR-cAMP pathway thereby
promote cancer stemness and metastasis. Interestingly, cAMP
signaling affects ERK activation independent on Raf-MEK signaling
pathway driven by MUC15 over-expression
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GFP-expressing vectors to monitor the GFP ﬂuorescence
signal using IVIS image system (Xenogen) every 5 days up
to day 30. Once bearing palpable tumors (about 4 weeks
after tumor cell inoculation), mice were euthanized and
their tumors were isolated, and photographed. Experi-
ments were performed in triplicate.
Human samples
Human tumor samples were collected from patients
enrolled on Institutional Review Board approved trials at
Yonsei Hospital (IRB 4-2012-0682). Specimens were col-
lected after obtaining written informed consent prior to
undergoing any study-speciﬁc procedures in accordance
with the Declaration of Helsinki. Patient’s identity of
pathological specimens remained anonymous in the
context of this study.
RNA extraction and cDNA synthesis
In order to perform RT-qPCR and NGS sequencing,
total content of cellular RNA was extracted from 80%
conﬂuence cells using an RNeasy Mini kit (Qiagen, USA)
in accordance with the manufacture’s protocol. For cDNA
synthesis, 1 μg of RNA was used as a template to reverse-
transcribe the RNA into template DNA in accordance
with the instructions of the ReverTra Ace qPCR RT kit
(Toyobo, Japan). Polymerase chain reaction (PCR) was
carried out to assess differences in mRNA expression of
the aforementioned genes. The products were electro-
phoresed on a 2% agarose gel to visualize the differences
in mRNA expression. Similarly, to further validate the
results, a more sensitive quantitative PCR (qPCR) was
carried out using SYBR green from Biorad.
Transfection
To develop an overexpression vector for MUC15, the
pMSCV puro (lentivirus) vector was used. MUC15 gene
was isolated from MUC15-expressing colon cancer cells
and was used for complementary DNA (cDNA) synthesis.
MUC15 cDNA was cloned into pMSCV puro vector and
transfected into Nthy-ori 3-1 cells, followed by puromycin
treatment for selection.
Lentiviral constructs containing MUC15-speciﬁc
shRNA conjugated with puromycin resistance genes and
tGFP was obtained from Sigma Aldrich (MO, USA). To
generate the lentivirus, tGFP-shRNA of Lenti vector and
packaging vectors were used to co-transfect with
HEK293T cells in accordance with the manufacturer’s
instructions. Viral supernatants were harvested and used
to transduce FTC-238 cells. Transduction efﬁciency was
analyzed via qPCR and western blotting analyses.
RNA sequencing
Total cellular RNA was extracted from cells grown to
80% conﬂuence, using an RNeasy Mini Kit (Qiagen) in
accordance with the manufacturer’s protocol. The total
RNA was sent to Macrogen (Korea) for sequencing.
Proliferation assay
Cells were seeded in triplicate wells in 96-well plates at
2000 cells per well and treated with PrestoBlue® Cell
Viability Reagent (Invitrogen) for the proliferation assay in
accordance with the manufacturer’s protocol. The
experiment was performed every day for 7 days.
Apoptosis assay
Cells were seeded in triplicate wells in six-well low-
attachment plates at 5 × 104 cells per well. After incuba-
tion for 1 days, 3 days, and 5 days, cells were harvested.
Apoptosis was assayed using the Annexin-V apoptosis
Detection Kit (eBioscience, UK) in accordance with the
manufacturer’s instructions. Cells were washed once with
100 µl Binding Buffer and stained for 10min with
Annexin-V at room temperature in dark. Stained cells
were washed once with 200 µl Binding Buffer and stained
again with 7-Aminoactinomycin D. Stained cells were
analyzed using a BD ﬂuorescence-activated cell sorting
Canto ﬂow cytometer (BD Biosciences, UK).
Sphere forming assay
Cells with greater stemness or self-renewal ability are
likely to form spheres, which are more in number and
bigger in diameter, when cultured in special media. This
property was exploited in the following assay. Indicated
cells were seeded at 5000 cells/well in triplicate in six-well
low-attachment plates. Cells were cultured in Phenol-red
free DMEM/F12 (Gibco) containing 1ml of
B27 supplement minus vitamin A (50×) (Gibco), 5 µl of
rhEGF (100 µg/ml) (R&D System, UK), 100 µl of bFGF
(10 µg/ml) (BD), 100 IU/ml penicillin, and 100 µg/ml
streptomycin (Invitrogen). The cells were incubated for
5 days at 37 °C and 5% CO2 for sphere formation. UO126
was purchased from cell signaling technology (MA, USA).
PTX and caffeine were purchased from Sigma Aldrich
(MO, USA).
Western blot analysis
Starvation was induced in the cells for 12 h in serum-
free media. Thereafter, growth factor hEGF (100 ng/ml)
(BD) was added and cells were incubated for 0, 10, 30, and
60min. Thereafter, cells were lysed in RIPA lysis buffer
containing 1mL of RIPA buffer (10×) (Millionpore),
100 µl PMSF (Sigma), and 1 table of protease inhibitor.
Collected the cell lysate were subject to spin-down by
centrifuges at 13,000 × g for 15 min and only supernatant
was used for western blot analysis. Protein lysates were
quantiﬁed and mixed with 4X loading dye (10 ml of
NuPAGE LDS Sample Buffer (4×) and 500 µl of beta-
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mercaptoethanol) at 20 µg/16 µl and heated at 95 °C for
5 min. Sixteen microliters of protein sample was loaded
onto a polyacrylamide gel (12%), which was run at 100 V
for 2 h and the proteins were then electroblotted onto
Immuno-Blot PVDF Membrane (Biorad, USA) for 1 h at
250mA, on ice. The membrane was then incubated with
primary during overnight at 4 °C and secondary anti-
bodies for 1 h at room temperature with agitation. ECL
Prime Western blotting reagent (Amersham, UK) was
used to develop the membrane. The primary antibodies
were as follows: anti-MUC15 (Novus, USA), anti-total
BRAF, anti-phospho-BRAF (Ser445), anti-total c-RAF,
anti-phospho-c-RAF (Ser338), anti-total MEK, anti-phos-
pho-MEK, anti-total ERK1/2, and anti-phosphor-ERK1/2
(Cell signaling technology, USA). β-actin was used as the
control and detected with anti-β-actin rabbit polyclonal
antibody (Sigma-Aldrich, USA). Anti-rabbit secondary
antibody was purchased from Dako (USA).
Statistical analysis
All quantiﬁed experimental data are expressed as mean
± SD values. To test statistical difference, student’s t-test
and one-way ANOVA were conducted. GraphPad Prism
7.0 (GraphPad Software Inc., San Diego, CA, USA) was
used for statistics analysis and *P < 0.05, **P < 0.01, and
***P < 0.001 values were used as signiﬁcant values.
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